Taken together, our data reveal that the oncosuppressor P53 counteracts NKX3-2 expression in ovarian cancer cells and supports the prognostic value of NKX3-2 for the stratification of cancer patients in a view of precision medicine. This evidence concerns the gene TP53 and ovarian carcinoma.